Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Orchestra BioMed Holdings ( (OBIO) ) has issued an update.
On June 24, 2025, Orchestra BioMed Holdings, Inc. held its Annual Meeting of Stockholders, where stockholders voted on two key proposals. The election of three Class II directors, Chris Cleary, Pamela Connealy, and David Pacitti, was confirmed, and the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
The most recent analyst rating on (OBIO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Orchestra BioMed Holdings stock, see the OBIO Stock Forecast page.
Spark’s Take on OBIO Stock
According to Spark, TipRanks’ AI Analyst, OBIO is a Underperform.
Orchestra BioMed Holdings has a low overall stock score primarily due to its poor financial performance, marked by substantial losses and negative cash flows. The bearish technical indicators further constrain the score. While recent FDA approvals are promising, they do not immediately impact the financial health or valuation of the company.
To see Spark’s full report on OBIO stock, click here.
More about Orchestra BioMed Holdings
Orchestra BioMed Holdings, Inc. operates in the biomedical industry, focusing on the development and commercialization of high-impact medical devices and therapies.
Average Trading Volume: 429,701
Technical Sentiment Signal: Sell
Current Market Cap: $115.3M
For detailed information about OBIO stock, go to TipRanks’ Stock Analysis page.